Using CD47's protection to deliver anti-cancer drugs directly to tumor cells

October 9, 2012 by Marcia Goodrich
Ching-An Peng with students in his lab. Peng is studying new ways to get chemotherapy drugs to the site of a tumor.

(Medical Xpress)—For most of their natural lives, red blood cells hide safely under the radar of the body's immune system, thanks to a cloak of "don't eat me" protein called CD47. Ching-An Peng of Michigan Technological University wants to co-opt that clever trick to fight cancer.

Voracious called macrophages normally protect organisms by engulfing cell debris and pathogens. However, if they encounter something covered with CD47, such as a red blood cell, they tend to leave it alone. "I thought, 'Why not use CD47 to help deliver drugs?" said Peng. "We could camouflage them and avoid the immune response."

Nanoparticles hold great promise for delivering anti- directly to the site of a tumor. Getting them there, however, has been problematic, since macrophages stand at the ready to scoop the particles out of the blood stream before they can get to the the tumor and drop their cargo. Peng theorizes that if drug-bearing nanoparticles were coated with CD47, they could make it to the tumor unmolested.

CD47 also brings another weapon to the war against cancer. It binds to a special kind of protein found on tumors called an integrin. This integrin is involved with the network of that form around the tumor, blood vessels that provide the cancer with nutrients to fuel its out-of-control growth.

Thus, properly designed CD47-coated nanoparticles might deliver a one-two punch to cancer by 1) delivering and 2) choking off its food supply.

Research by Peng and his colleagues is in its early stages. They are using E. coli bacteria to mass produce CD47 in the lab using recombinant DNA technology. The next step will be to attach it to nanoparticles and expose them to macrophages, to see if the macrophages eat them up or—hopefully—ignore them.

Explore further: Research: Single antibody shrinks variety of human tumors transplanted into mice

Related Stories

Research: Single antibody shrinks variety of human tumors transplanted into mice

March 26, 2012
Human tumors transplanted into laboratory mice disappeared or shrank when scientists treated the animals with a single antibody, according to a new study from the Stanford University School of Medicine. The antibody works ...

Recommended for you

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

Scientists restore tumor-fighting structure to mutated breast cancer proteins

September 20, 2017
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides ...

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

Researchers identify new target, develop new drug for cancer therapies

September 20, 2017
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to ...

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.